Trial Profile
A phase I/II study of crizotinib for recurrent or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and phase I study of this drug for recurrent or refractory neuroblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 Jul 2022
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Anaplastic large cell lymphoma; Neuroblastoma
- Focus Adverse reactions; Therapeutic Use
- 11 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 11 Jul 2022 Planned End Date changed from 30 Sep 2022 to 31 Dec 2022.
- 25 Mar 2019 Status changed from suspended to recruiting.